Skip to content
Facebook Twitter Linkedin
InMed-logo-01
  • Pharmaceutical
    • INM-901 for Alzheimer’s Disease
    • INM-089 for Age-related Macular Degeneration
    • INM-755 for Epidermolysis Bullosa
    • INM-088 for Glaucoma
    • Novel Analogs
  • Manufacturing
    • BayMedica – Rare Cannabinoid Ingredients
    • Cannabinoid Manufacturing Expertise
    • IntegraSyn™ Cannabinoid Manufacturing
  • Investors
    • News Releases
    • Events
    • Stock Information
    • Corporate Governance
    • Financials & AGM Materials
    • Filings
    • Presentations
    • Media and Videos
    • Investor Contact
  • Corporate
    • Management
    • Board of Directors
    • Scientific Advisors
    • Partners and Collaborators
    • Careers
    • Contact
  • Learn
  • Pharmaceutical
    • INM-901 for Alzheimer’s Disease
    • INM-089 for Age-related Macular Degeneration
    • INM-755 for Epidermolysis Bullosa
    • INM-088 for Glaucoma
    • Novel Analogs
  • Manufacturing
    • BayMedica – Rare Cannabinoid Ingredients
    • Cannabinoid Manufacturing Expertise
    • IntegraSyn™ Cannabinoid Manufacturing
  • Investors
    • News Releases
    • Events
    • Stock Information
    • Corporate Governance
    • Financials & AGM Materials
    • Filings
    • Presentations
    • Media and Videos
    • Investor Contact
  • Corporate
    • Management
    • Board of Directors
    • Scientific Advisors
    • Partners and Collaborators
    • Careers
    • Contact
  • Learn

IntegraSyn™ - Manufacturing System for Pharmaceutical-Grade Cannabinoids

IntegraSyn™ is InMed’s flexible, integrated cannabinoid manufacturing system 
to efficiently produce pharmaceutical-grade, bio-identical cannabinoids.

IntegraSyn™ – An optimized system to cannabinoid manufacturing

IntegraSyn™ is InMed’s integrated cannabinoid synthesis system to manufacture pharmaceutical-grade cannabinoids. Our goal has always been to achieve an efficient, scalable, flexible and economical solution to produce cannabinoids with bio-identical structures to those found in nature. IntegraSyn™ is designed to produce rare cannabinoids for pharmaceutical use. In addition to IntegraSyn™, InMed’s subsidiary, BayMedica, utilizes biosynthesis and chemical synthesis to manufacture rare cannabinoids for the health and wellness industry.

Achieving commercially viable yield

In further optimization testing at small scale, InMed was able to achieve a cannabinoid yield of 5 g/L, a commercially viable yield that significantly exceeds currently reported industry yields. 

A cost-effective solution to multi-cannabinoid production

IntegraSyn™ makes cost-efficient use of sophisticated starting materials, requires fewer costly steps all the way through to the end-product, and is designed as a high-yield manufacturing process. We produce high-efficiency enzymes utilizing E. coli biofermentation for use in bulk cannabinoid manufacturing via a biotransformation process and further purification steps. The resulting cannabinoid can be used either as a finished cannabinoid product or as a starting material to produce other cannabinoids using any one of several well-established manufacturing approaches.

Flexibility to shift production of one cannabinoid to a range of cannabinoids

The flexible IntegraSyn™ manufacturing system integrates various pharmaceutical manufacturing processes to optimize production of cannabinoids. While traditional biosynthesis and chemical synthesis focus on production of one cannabinoid from start to finish, the modular IntegraSyn™ process provides flexibility to shift production of one cannabinoid to a range of cannabinoids. This modular approach places less burden on the fermentation microbe and allows for the use of different enzymes and starting materials, leading to optimized yield, time and cost.

Meeting the cannabinoid needs of our therapeutic programs and future markets

InMed is focused on the development of cannabinoid-based therapeutics to treat serious diseases with high unmet medical needs. We currently have four development programs in dermatological, neurodegenerative and ocular diseases, including INM-755 cannabinol (CBN) cream under development for epidermolysis bullosa, INM-901 under development for the treatment of Alzheimer’s disease, INM-088 under development for glaucoma and INM-089 under development for age-related macular degeneration. IntegraSyn™ has been developed by InMed to supply rare, pharmaceutical-grade, bio-identical cannabinoids for its own development programs and eventual commercial needs.

Gaining access to rare cannabinoids

There are more than 100 rare cannabinoids found in only trace amounts in the Cannabis plant – together making up less than 1% of the plant biomass. Evidence suggests that even slight differences in the chemical structure of cannabinoids can result in meaningful differences in biological activity, safety and therapeutic effects in the human body. While rare cannabinoids may hold promise as new treatment options, their low levels in the plant make them impractical to extract for pharmaceutical or any large-scale purpose. IntegraSyn™ was developed to enable access to these rare cannabinoids cost-effectively, at pharmaceutical-grade while being bio-identical to those found in the plant.

Scalable, pharmaceutical-grade cannabinoids to meet future market demand

IntegraSyn™ is designed to be scalable and to produce the consistent, compliant, highly pure cannabinoids required for pharmaceutical products. While having the potential to supply InMed’s own development and future commercialization needs, IntegraSyn™ may be able to supply rare cannabinoids, not previously accessible, to other companies, potentially opening up new product and market opportunities.

Integrated cannabinoid synthesis suitable for long-term needs

Challenges of plant-based Cannabis production, including the large footprint of greenhouses or exterior fields, use of pesticides and fertilizers, security requirements and inconsistent levels of the active compounds, make the synthetic approach of cannabinoid manufacturing a better longer-term strategy for pharmaceutical development and supply. The current traditional method to obtain cannabinoids – plant, grow, harvest, extract and purify – is not feasible for long-term pharmaceutical demand.

A synthetic process provides for a reliable, consistent, scalable and compliant process versus the variability and complexity associated with the extraction and purification of the cannabinoids directly from the plant.

As interest in the therapeutic potential of cannabinoids continues to grow, IntegraSyn™ may be the solution to provide access to a range of cost-effective, bio-identical cannabinoids.


INM-755

A cannabinol (CBN) topical cream which has completed a Phase 2 clinical trial for epidermolysis bullosa
Learn More

INM-088

A cannabinol (CBN) formulation in preclinical development for the treatment of glaucoma
Learn More

Investor Alerts

Sign up for investor alerts!
Sign Up
InMed-logo-mono

#1455 – 885 West Georgia St.
Vancouver, BC, Canada
V6C 3E8

Pharmaceutical

  • INM-901 for Alzheimer’s Disease
  • INM-089 for Age-related Macular Degeneration
  • INM-755 for Epidermolysis Bullosa
  • INM-088 for Glaucoma
  • Novel Analogs

MANUFACTURING

  • BayMedica – Rare Cannabinoid Ingredients
  • Cannabinoid Manufacturing Expertise
  • IntegraSyn™ Cannabinoid Manufacturing

Investor

  • News
  • Events
  • Stock Information
  • Corporate Governance
  • Financials & AGM Materials
  • Filings
  • Presentations
  • Media & Videos
  • Investor Contact

CORPORATE

  • Management
  • Board of Directors
  • Scientific Advisors
  • Partners and Collaborators
  • Careers
  • Contact

Learn

  • What is Cannabinol (CBN)?
  • What is Epidermolysis Bullosa (EB)?
  • What is Glaucoma?
  • Cannabinoid Manufacturing Economics 101
  • GMP Manufacturing Standards by Product Type
  • Cannabinoids for Glaucoma
  • Cannabinoid Science
  • Articles and Videos

© Copyright 2025 InMed Pharmaceuticals Inc.

  • Privacy Policy
  • Terms of Use
  • Legal Disclaimer
  • Find Us On:
Subscribe

Sign up to receive emails from InMed Pharmaceuticals

"*" indicates required fields

Name*
Consent*